HUTCHMED (China) Limited (0013.HK)
HKD 23.0
(-0.22%)
HKD 23.0
(-0.22%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 100.78 Million USD | 124.57% |
| 2022 | -410.13 Million USD | -80.16% |
| 2021 | -227.65 Million USD | -17.01% |
| 2020 | -194.56 Million USD | -34.76% |
| 2019 | -144.37 Million USD | -93.01% |
| 2018 | -74.8 Million USD | -179.78% |
| 2017 | -26.73 Million USD | -328.56% |
| 2016 | 11.69 Million USD | 46.35% |
| 2015 | 7.99 Million USD | 48.73% |
| 2014 | 5.37 Million USD | -9.15% |
| 2013 | 5.91 Million USD | 62.59% |
| 2012 | 3.63 Million USD | 412.23% |
| 2011 | 710.22 Thousand USD | 110.35% |
| 2010 | -6.86 Million USD | 21.55% |
| 2009 | -8.74 Million USD | 50.72% |
| 2008 | -17.75 Million USD | -3.29% |
| 2007 | -17.18 Million USD | -78.94% |
| 2006 | -9.6 Million USD | -41.77% |
| 2005 | -6.77 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 12.9 Million USD | 138.07% |
| 2024 Q2 | 12.9 Million USD | 0.0% |
| 2023 Q1 | 84.27 Million USD | 185.14% |
| 2023 FY | 100.78 Million USD | 124.57% |
| 2023 Q4 | -33.88 Million USD | 0.0% |
| 2023 Q3 | -33.88 Million USD | -140.21% |
| 2023 Q2 | 84.27 Million USD | 0.0% |
| 2022 Q2 | -81.43 Million USD | 0.0% |
| 2022 Q3 | -98.98 Million USD | -21.56% |
| 2022 FY | -410.13 Million USD | -80.16% |
| 2022 Q4 | -98.98 Million USD | 0.0% |
| 2022 Q1 | -81.43 Million USD | -76.54% |
| 2021 Q4 | -46.12 Million USD | 0.0% |
| 2021 Q3 | -46.12 Million USD | 40.45% |
| 2021 FY | -227.65 Million USD | -17.01% |
| 2021 Q2 | -77.46 Million USD | -19.45% |
| 2021 Q1 | -64.84 Million USD | -70.57% |
| 2020 Q3 | -38.01 Million USD | 17.79% |
| 2020 FY | -194.56 Million USD | -34.76% |
| 2020 Q1 | -32.36 Million USD | -9.48% |
| 2020 Q2 | -46.24 Million USD | -42.89% |
| 2020 Q4 | -38.01 Million USD | 0.0% |
| 2019 Q2 | -34.54 Million USD | -73.73% |
| 2019 Q1 | -19.88 Million USD | -20.25% |
| 2019 FY | -144.37 Million USD | -93.01% |
| 2019 Q4 | -29.56 Million USD | 4.92% |
| 2019 Q3 | -31.09 Million USD | 10.0% |
| 2018 Q3 | -25.57 Million USD | -22.03% |
| 2018 FY | -74.8 Million USD | -179.78% |
| 2018 Q2 | -20.96 Million USD | -78.7% |
| 2018 Q1 | -11.73 Million USD | 17.45% |
| 2018 Q4 | -16.53 Million USD | 35.35% |
| 2017 FY | -26.73 Million USD | -328.56% |
| 2017 Q4 | -14.2 Million USD | 0.0% |
| 2017 Q1 | 841 Thousand USD | -84.93% |
| 2017 Q3 | -14.2 Million USD | -1789.6% |
| 2017 Q2 | 841 Thousand USD | 0.0% |
| 2016 FY | 11.69 Million USD | 46.35% |
| 2016 Q4 | 5.58 Million USD | 0.0% |
| 2016 Q3 | 5.58 Million USD | 1978.4% |
| 2016 Q2 | 268.5 Thousand USD | 0.0% |
| 2016 Q1 | 268.5 Thousand USD | -92.01% |
| 2015 Q1 | -13.03 Million USD | -232.79% |
| 2015 FY | 7.99 Million USD | 48.73% |
| 2015 Q4 | 3.35 Million USD | 43.73% |
| 2015 Q3 | 2.33 Million USD | 117.93% |
| 2015 Q2 | -13.03 Million USD | 0.0% |
| 2014 Q2 | 2.34 Million USD | 0.0% |
| 2014 Q1 | 2.34 Million USD | -87.86% |
| 2014 Q4 | 9.81 Million USD | 190.14% |
| 2014 FY | 5.37 Million USD | -9.15% |
| 2014 Q3 | -10.88 Million USD | -563.56% |
| 2013 Q1 | 2.62 Million USD | -31.54% |
| 2013 Q2 | 2.62 Million USD | 0.0% |
| 2013 Q3 | 1.31 Million USD | -49.83% |
| 2013 Q4 | 19.34 Million USD | 1367.24% |
| 2013 FY | 5.91 Million USD | 62.59% |
| 2012 FY | 3.63 Million USD | 412.23% |
| 2012 Q4 | 3.83 Million USD | 0.0% |
| 2012 Q3 | 3.83 Million USD | 0.0% |
| 2011 FY | 710.22 Thousand USD | 110.35% |
| 2010 FY | -6.86 Million USD | 21.55% |
| 2009 FY | -8.74 Million USD | 50.72% |
| 2008 FY | -17.75 Million USD | -3.29% |
| 2007 FY | -17.18 Million USD | -78.94% |
| 2006 FY | -9.6 Million USD | -41.77% |
| 2005 FY | -6.77 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | 4.055% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 94.639% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 161.848% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 756.291% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 291.215% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | -503.545% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 63.387% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 449.409% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 195.003% |
| SSY Group Limited | 1.31 Billion HKD | 92.357% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 22.752% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 62.25% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 97.385% |